A detailed history of Lazard Asset Management LLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 98 shares of IBRX stock, worth $310. This represents 0.0% of its overall portfolio holdings.

Number of Shares
98
Previous 270 63.7%
Holding current value
$310
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.32 - $6.7 $571 - $1,152
-172 Reduced 63.7%
98 $0
Q2 2024

Aug 14, 2024

SELL
$4.82 - $9.15 $61,450 - $116,653
-12,749 Reduced 97.93%
270 $1,000
Q1 2024

May 14, 2024

BUY
$3.23 - $6.17 $21,295 - $40,678
6,593 Added 102.6%
13,019 $68,000
Q4 2023

Feb 14, 2024

BUY
$1.25 - $5.21 $323 - $1,349
259 Added 4.2%
6,426 $32,000
Q3 2023

Nov 14, 2023

BUY
$1.29 - $3.1 $345 - $830
268 Added 4.54%
6,167 $10,000
Q2 2023

Aug 14, 2023

BUY
$1.53 - $6.41 $9,025 - $37,812
5,899 New
5,899 $16,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.27B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.